BSH 2019 | Daunorubicin and cytarabine approved for AML treatment within NHS Scotland

Name: Daunorubicin and cytarabine approved for AML treatment within NHS Scotland
Uploaded: 2019-04-01T16:36:02.000Z
Duration: 53 s
Description: Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Zack Pemberton-Whiteley • 1 Apr 2019

BSH 2019

Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin

Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.